28 min

284: AbbVie’s big deal, CAR-T’s risks, & getting a biotech job The Readout Loud

    • Business

We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology. We’ll also talk about the latest news in the life sciences, including safety concerns for CAR-T cancer treatment, the slumping industry job market, and some curious explanations for clinical failures.

We discuss why AbbVie is spending $10 billion on a cancer-focused company that spent four decades on the path to its first FDA approval, a deal with implications for biotech in 2023 and for a burgeoning area in oncology. We’ll also talk about the latest news in the life sciences, including safety concerns for CAR-T cancer treatment, the slumping industry job market, and some curious explanations for clinical failures.

28 min

Top Podcasts In Business

NerdWallet Personal Finance
Ramsey Network
Money News Network
Dan Fleyshman
Hala Taha | YAP Media Network
Her First $100K